Clamour for GSK shingles shot points to bigger profits

GlaxoSmithKline is facing "unprecedented" demand for its new shingles vaccine Shingrix, suggesting the product could be a bigger money-spinner than the company and analysts initially thought.GSK said it had increased deliveries significantly and was vaccinating people against shingles far faster than in the past, when Merck & Co's Zostavax was the only product available."The arrival of Shingrix has been met with an unprecedented level of demand from patients and healthcare professionals," a